Market overview
The global biobanking market is worth USD 3.2 bn in 2026 and is forecast to reach USD 7.3 bn by 2036, growing at a 8.5% CAGR. United States is the largest country market and Equipment and freezers is the largest by product segment.
| Scope | Facilities, freezers, consumables, software and storage services for collecting, processing and storing human biological samples for research, clinical and cell therapy use. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 3.0 bn |
| Value 2026 | USD 3.2 bn |
| Value 2036 | USD 7.3 bn |
| CAGR 2026-2036 | 8.5% |
| Volume 2026 | 645 million samples stored |
| Volume 2036 | 1,387 million samples stored |
| Average price 2026 | USD 5.03 per samples stored |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Biobanking market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 3.2 bn |
| 2027 | USD 3.5 bn |
| 2028 | USD 3.8 bn |
| 2029 | USD 4.1 bn |
| 2030 | USD 4.5 bn |
| 2031 | USD 4.9 bn |
| 2032 | USD 5.3 bn |
| 2033 | USD 5.7 bn |
| 2034 | USD 6.2 bn |
| 2035 | USD 6.8 bn |
| 2036 | USD 7.3 bn |
Biobanking market segmentation
By product
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Equipment and freezers | 34.0% | 29.8% | USD 1.1 bn | 7.1% |
| Consumables | 30.0% | 28.8% | USD 972 mn | 8.1% |
| Storage and processing services | 28.0% | 30.9% | USD 907 mn | 9.6% |
| Software and information systems | 8.0% | 10.6% | USD 259 mn | 11.6% |
By sample
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Blood products | 28.0% | 27.0% | USD 907 mn | 8.1% |
| Tissue and cells | 26.0% | 27.4% | USD 842 mn | 9.1% |
| Nucleic acids | 18.0% | 19.0% | USD 583 mn | 9.1% |
| Stem cells and cord blood | 20.0% | 19.3% | USD 648 mn | 8.1% |
| Other samples | 8.0% | 7.4% | USD 259 mn | 7.6% |
By use
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Drug discovery and research | 44.0% | 42.3% | USD 1.4 bn | 8.1% |
| Clinical trials | 24.0% | 23.1% | USD 778 mn | 8.1% |
| Cell and gene therapy | 18.0% | 21.7% | USD 583 mn | 10.6% |
| Personalised medicine and other | 14.0% | 12.9% | USD 454 mn | 7.6% |
By storage temperature
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Ultra-low freezers | 34.0% | 33.0% | USD 1.1 bn | 8.2% |
| Liquid nitrogen | 28.0% | 30.0% | USD 907 mn | 9.2% |
| Refrigerated | 22.0% | 20.0% | USD 713 mn | 7.5% |
| Ambient | 16.0% | 17.0% | USD 518 mn | 9.2% |
By ownership
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Academic biobanks | 34.0% | 32.0% | USD 1.1 bn | 7.8% |
| Hospital biobanks | 24.0% | 23.0% | USD 778 mn | 8.0% |
| Commercial biobanks | 26.0% | 29.0% | USD 842 mn | 9.7% |
| Government and population | 16.0% | 16.0% | USD 518 mn | 8.5% |
Top 25 countries for biobanking by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 87.0% of 2026 revenue and the 25 countries below together hold 97.7%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 1.4 bn | 42.0% | USD 2.9 bn | 8.0% |
| 2 | China | USD 292 mn | 9.0% | USD 864 mn | 11.5% |
| 3 | United Kingdom | USD 227 mn | 7.0% | USD 491 mn | 8.0% |
| 4 | Germany | USD 227 mn | 7.0% | USD 491 mn | 8.0% |
| 5 | Japan | USD 162 mn | 5.0% | USD 330 mn | 7.4% |
| 6 | France | USD 130 mn | 4.0% | USD 278 mn | 7.9% |
| 7 | Canada | USD 130 mn | 4.0% | USD 278 mn | 7.9% |
| 8 | Denmark | USD 97 mn | 3.0% | USD 220 mn | 8.5% |
| 9 | India | USD 97 mn | 3.0% | USD 278 mn | 11.1% |
| 10 | Australia | USD 97 mn | 3.0% | USD 220 mn | 8.5% |
| 11 | Sweden | USD 49 mn | 1.5% | USD 108 mn | 8.2% |
| 12 | Singapore | USD 46 mn | 1.4% | USD 115 mn | 9.5% |
| 13 | Switzerland | USD 35 mn | 1.1% | USD 77 mn | 8.2% |
| 14 | Belgium | USD 29 mn | 0.9% | USD 64 mn | 8.1% |
| 15 | Finland | USD 28 mn | 0.9% | USD 62 mn | 8.2% |
| 16 | Spain | USD 28 mn | 0.9% | USD 62 mn | 8.2% |
| 17 | Italy | USD 21 mn | 0.7% | USD 46 mn | 8.2% |
| 18 | South Korea | USD 20 mn | 0.6% | USD 50 mn | 9.5% |
| 19 | Brazil | USD 19 mn | 0.6% | USD 47 mn | 9.4% |
| 20 | Israel | USD 17 mn | 0.5% | USD 37 mn | 8.1% |
| 21 | Norway | USD 13 mn | 0.4% | USD 28 mn | 8.2% |
| 22 | Taiwan | USD 12 mn | 0.4% | USD 29 mn | 9.3% |
| 23 | Poland | USD 9.7 mn | 0.3% | USD 24 mn | 9.5% |
| 24 | Mexico | USD 9.4 mn | 0.3% | USD 23 mn | 9.2% |
| 25 | Netherlands | USD 8.8 mn | 0.3% | USD 19 mn | 8.1% |
| Rest of world | USD 76 mn | 2.3% | USD 155 mn | 7.4% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Thermo Fisher Scientific
- Azenta
- Merck KGaA
- Danaher
- Hamilton Company
Group 2: Regional and specialist players
- Cryoport
- Tecan
- BioLife Solutions
- Greiner Bio-One
- Sartorius
- PHC Holdings
- Haier Biomedical
- Chart Industries
- LabVantage Solutions
Group 3: Emerging and niche players
- BioIVT
- Cryo-Cell International
- Cordlife Group
- Precision for Medicine
- CBR Systems
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the biobanking market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 8.5% is calculated from the resulting values.
The market is divided by product, by sample, by use, by storage temperature, by ownership. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the biobanking market?
The global biobanking market is estimated at USD 3.0 bn in 2025 and USD 3.2 bn in 2026.
How fast will the biobanking market grow?
It is forecast to reach USD 7.3 bn by 2036, a compound annual growth rate of 8.5% from 2026, an increase of USD 4.1 bn.
Which country is the largest market for biobanking?
United States is the largest market by revenue at USD 1.4 bn in 2026, 42.0% of the global total. The three largest countries together hold 58.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 11.5% a year from 2026 to 2036.
Which biobanking segment is largest?
In the by product split, Equipment and freezers is the largest segment with 34.0% of 2026 revenue.
Who are the leading biobanking companies?
Global leaders include Thermo Fisher Scientific, Azenta, Merck KGaA, Danaher.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Lyophilization EquipmentUSD 3.1 bn · 7.6% CAGR
- Neurorehabilitation TechnologyUSD 3.4 bn · 9.0% CAGR
- CapsuleUSD 3.4 bn · 6.5% CAGR
- Continuous Positive Airway Pressure (CPAP)USD 3.1 bn · 6.5% CAGR
- Enzyme Linked Immunosorbent AssayUSD 3.1 bn · 5.2% CAGR
- Healthcare Provider Workflow OptimizationUSD 3.4 bn · 10.5% CAGR
- Spray DryingUSD 3.0 bn · 5.3% CAGR
- ImmunohistochemistryUSD 3.5 bn · 8.0% CAGR